← Leaderboards
Thomas Dick
Rbhs-New Jersey Medical School
$15,241,285
Attributed
$18,108,045
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,108,045 · 6
By mechanism
R01$13,536,650 · 4
U19$4,571,395 · 2
Top collaborators
- Veronique Dartois4 shared
- Courtney C Aldrich3 shared
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoInfectionAnalogMouse ModelPharmaceutical PreparationsProgramsResistanceAntibioticsBacteriaDrug KineticsLeadTuberculosisPropertyMycobacterium TuberculosisSitePharmacologyLungNon-Tuberculosis MycobacteriaPathogenMycobacterium AbscessusChemistryLung DiseasesMedicinePreclinical Development
Grant awards (22)
Novel rifamycins to improve cure rates and shorten treatment of M. abscessus lung disease$941,394
U19 · FY2025 · AI · contact PI
Shorter and more effective oral regimens for M. abscessus pulmonary disease$895,538
R01 · FY2025 · AI · contact PI
Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease$872,777
R01 · FY2025 · AI · contact PI
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease$838,280
R01 · FY2025 · AI · contact PI
Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease$892,054
R01 · FY2024 · AI · contact PI
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease$838,280
R01 · FY2024 · AI · contact PI
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease$857,555
R01 · FY2023 · AI · contact PI
New drugs for non-tuberculous mycobacterial (NTM) lung disease in patients with cystic fibrosis$703,425
U19 · FY2023 · AI · contact PI
Combatting natural resistance and persistence in non-TB mycobacterial disease$906,704
R01 · FY2022 · AI · contact PI
Target based discovery of next generation pyrazinamide$791,696
R01 · FY2022 · AI · contact PI
New drugs for non-tuberculous mycobacterial (NTM) lung disease in patients with cystic fibrosis$734,965
U19 · FY2022 · AI · contact PI
Combatting natural resistance and persistence in non-TB mycobacterial disease$906,704
R01 · FY2021 · AI · contact PI
Target based discovery of next generation pyrazinamide$794,409
R01 · FY2021 · AI
New drugs for non-tuberculous mycobacterial (NTM) lung disease in patients with cystic fibrosis$722,728
U19 · FY2021 · AI · contact PI
Combatting natural resistance and persistence in non-TB mycobacterial disease$906,704
R01 · FY2020 · AI · contact PI
Target based discovery of next generation pyrazinamide$797,081
R01 · FY2020 · AI
New drugs for non-tuberculous mycobacterial (NTM) lung disease in patients with cystic fibrosis$734,964
U19 · FY2020 · AI · contact PI
Combatting natural resistance and persistence in non-TB mycobacterial disease$859,392
R01 · FY2019 · AI · contact PI
Target based discovery of next generation pyrazinamide$838,267
R01 · FY2019 · AI
New drugs for non-tuberculous mycobacterial (NTM) lung disease in patients with cystic fibrosis$733,919
U19 · FY2019 · AI · contact PI
Combatting natural resistance and persistence in non-TB mycobacterial disease$771,560
R01 · FY2018 · AI · contact PI
Target based discovery of next generation pyrazinamide$769,649
R01 · FY2018 · AI